Attributes | Values |
---|
rdf:type
| |
http://linked.open...gbank/description
| - Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread of seizure activity rather than to abolish the primary focus of seizure discharges. Ethotoin is no longer commonly used. (en)
|
http://linked.open...y/drugbank/dosage
| |
http://linked.open...generalReferences
| - # SCHWADE ED, RICHARDS RK, EVERETT GM: Peganone, a new antiepileptic drug. Dis Nerv Syst. 1956 May;17(5):155-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/13317788 (en)
|
http://linked.open...gy/drugbank/group
| |
http://linked.open...drugbank/halfLife
| |
http://linked.open...ugbank/indication
| - For the control of tonic-clonic (grand mal) and complex partial (psychomotor) seizures. (en)
|
http://linked.open...bank/manufacturer
| |
sameAs
| |
Title
| |
adms:identifier
| |
http://linked.open...mechanismOfAction
| - The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread of seizure activity rather than to abolish the primary focus of seizure discharges. Ethotoin inhibits nerve impulses in the motor cortex by lowering sodium ion influx, limiting tetanic stimulation. (en)
|
http://linked.open...drugbank/packager
| |
http://linked.open.../drugbank/synonym
| - Ethotoin (en)
- (+-)-3-Ethyl-5-phenylhydantoin (en)
- 1-Ethyl-2,5-dioxo-4-phenylimidazolidine (en)
- 3-Ethyl-5-phenyl-2,4-imidazolidinedione (en)
- 3-Ethyl-5-phenyl-imidazolidine-2,4-dione (en)
- 3-Ethyl-5-phenylhydantoin (en)
- 3-Ethyl-5-phenylimidazolidin-2,4-dione (en)
- Ethotoinum (en)
- Ethotoïne (en)
- Etotoina (en)
|
http://linked.open...drugbank/toxicity
| - Symptoms of overdose include drowsiness, loss of or impaired muscle coordination, nausea, visual disturbance, and, at very high doses, coma. (en)
|
http://linked.open...ynthesisReference
| - Close, W.J.; U.S. Patent 2,793,157; May 21, 1957; assigned to Abbott Laboratories. (en)
|
foaf:page
| |
http://linked.open...ugbank/IUPAC-Name
| |
http://linked.open...gy/drugbank/InChI
| |
http://linked.open...Molecular-Formula
| |
http://linked.open.../Molecular-Weight
| |
http://linked.open...noisotopic-Weight
| |
http://linked.open...y/drugbank/SMILES
| |
http://linked.open.../Water-Solubility
| |
http://linked.open...ogy/drugbank/logP
| |
http://linked.open...ogy/drugbank/logS
| |
http://linked.open...l/drug/hasATCCode
| |
http://linked.open...nd-Acceptor-Count
| |
http://linked.open...-Bond-Donor-Count
| |
http://linked.open...drugbank/InChIKey
| |
http://linked.open...urface-Area--PSA-
| |
http://linked.open...nk/Polarizability
| |
http://linked.open...bank/Refractivity
| |
http://linked.open...atable-Bond-Count
| |
http://linked.open...ugbank/absorption
| - Fairly rapidly absorbed, however, the extent of oral absorption is not known. (en)
|
http://linked.open.../affectedOrganism
| - Humans and other mammals (en)
|
http://linked.open...casRegistryNumber
| |
http://linked.open...drugbank/category
| |
http://linked.open...gbank/containedIn
| |
http://linked.open...k/Bioavailability
| |
http://linked.open...bank/Ghose-Filter
| |
http://linked.open...nk/MDDR-Like-Rule
| |
http://linked.open...ank/Melting-Point
| |
http://linked.open...k/Number-of-Rings
| |
http://linked.open...siological-Charge
| |
http://linked.open...bank/Rule-of-Five
| |
http://linked.open...tional-IUPAC-Name
| |
http://linked.open...strongest-acidic-
| |
http://linked.open...-strongest-basic-
| |